IPSEN (OTCMKTS:IPSEY) Shares Gap Down – What’s Next?

Shares of IPSEN (OTCMKTS:IPSEY) gapped down before the market opened on Monday . The stock had previously closed at $47.68, but opened at $44.9475. IPSEN shares last traded at $44.9475, with a volume of 1,023 shares traded.

Wall Street Analyst Weigh In

Several brokerages recently commented on IPSEY. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of IPSEN in a research note on Thursday, May 14th. Jefferies Financial Group downgraded IPSEN from a “hold” rating to an “underperform” rating in a research note on Sunday. HC Wainwright reaffirmed a “buy” rating on shares of IPSEN in a research report on Tuesday, June 30th. Finally, Zacks Research raised shares of IPSEN to a “hold” rating in a research report on Friday, May 29th. Two research analysts have rated the stock with a Buy rating, two have given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold”.

IPSEN Price Performance

The business has a 50 day simple moving average of $45.77 and a 200 day simple moving average of $45.67.

IPSEN Company Profile

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).